Immunohistochemistry Market by Product, Disease Type, End-user, Application

List of Tables

The Immunohistochemistry Market was valued at USD 2.98 billion in 2023, expected to reach USD 3.15 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.46 billion by 2030.

Immunohistochemistry (IHC) is a critical technique that merges anatomical, immunological, and biochemical methods to identify specific antigens in cells by utilizing specific antibodies, thus offering a profound impact on diagnostic and pharmaceutical fields. The necessity of IHC lies in its capability to provide valuable insights into the pathogenesis of diseases like cancer, enabling the customization of treatment plans, enhancing diagnostic accuracy, and advancing therapeutic outcomes. Its application spans pathology, oncology, and drug development, serving crucial roles in hospitals, diagnostic laboratories, and research institutions. The expanding prevalence of chronic diseases, technological advancements, and an increasing demand for personalized medicine drive growth in this market. However, challenges such as high costs, the complexity of techniques, and limited availability of skilled professionals pose significant barriers. Key growth influences include an increase in cancer cases that necessitate precise diagnostics and the surge in biomarker research. Opportunities arise from technological innovations like digital pathology and automated platforms that boost efficiency and accuracy, as well as the development of multiplex assays that offer comprehensive analysis on a singular platform. To harness these opportunities, companies should focus on collaborative research, investing in advanced technologies, and expanding their product portfolios. However, navigating regulatory hurdles and maintaining rigorous quality control standards remain challenging. Innovations focusing on developing cost-effective, highly specific, and robust antibodies, along with leveraging AI for image analysis and novel diagnostic methods, represent promising research avenues. The market is dynamic, with a substantial emphasis on technological progression and strategic partnerships to broaden application capabilities. Thus, businesses that invest in cutting-edge technologies and robust R&D efforts are well-positioned to capitalize on the growing IHC market, addressing unmet needs and driving future growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.98 billion
Estimated Year [2024]	USD 3.15 billion
Forecast Year [2030]	USD 4.46 billion
CAGR (%)	5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunohistochemistry Market

The Immunohistochemistry Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Extensive prevalence of chronic diseases such as cancer and autoimmune diseases among population
- Increasing government funding and initiatives to improve cancer diagnostics
- Growing demand for personalized/customized medicine
Market Restraints
- Issues related to the collection, storage, and use of biopsy samples
Market Opportunities
- Introduction of automated and semi-automated immunohistochemistry systems
- Collaborations between diagnostic companies, research institutes, and healthcare
Market Challenges
- Concerns pertinent to product failure and shortage of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Immunohistochemistry Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunohistochemistry Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunohistochemistry Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunohistochemistry Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunohistochemistry Market

A detailed market share analysis in the Immunohistochemistry Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunohistochemistry Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunohistochemistry Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunohistochemistry Market

A strategic analysis of the Immunohistochemistry Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunohistochemistry Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies Inc., Becton, Dickinson & Company, Bio SB, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Biocare Medical LLC, Biogenex Laboratories, CANDOR Bioscience GmbH, Cell Signaling Technology, Inc., Danaher Corporation, Diagnostic BioSystems Inc., Eagle Biosciences, Inc., Elabscience Biotechnology Inc., F. Hoffman-La Roche AG, Genemed Biotechnologies, Inc. by Sakura Finetek Japan Co., Ltd, Histo-Line Laboratories, Lunaphore Technologies SA, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PerkinElmer Inc., Rockland Immunochemicals, Inc., Takara Bio, Inc, and Thermofisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Immunohistochemistry Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Antibodies, Equipment, Kits, and Reagents. The Antibodies is further studied across Primary Antibodies and Secondary Antibodies. The Equipment is further studied across Slide Scanners, Slide Staining Systems, Tissue Microarrays, and Tissue Processing Systems. The Reagents is further studied across Blocking Sera & Reagents, Chromogenic Substrates, Diluents, Fixation Reagents, Histological Stains, Organic Solvents, Proteolytic Enzymes, and Stabilizers.
Based on Disease Type, market is studied across Autoimmune Diseases, Cancer, Cardiovascular Diseases, Diabetes Mellitus, Infectious Diseases, and Nephrological Diseases.
Based on End-user, market is studied across Academic & Research Institutes, CROs, Forensic Labs, Hospitals & Diagnostic Laboratories, and Pharma & Biopharma Companies.
Based on Application, market is studied across Diagnostics, Drug Testing, and Forensic.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-A339DAEFADE0

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Extensive prevalence of chronic diseases such as cancer and autoimmune diseases among population
  - 5.1.1.2. Increasing government funding and initiatives to improve cancer diagnostics
  - 5.1.1.3. Growing demand for personalized/customized medicine
- 5.1.2. Restraints
  - 5.1.2.1. Issues related to the collection, storage, and use of biopsy samples
- 5.1.3. Opportunities
  - 5.1.3.1. Introduction of automated and semi-automated immunohistochemistry systems
  - 5.1.3.2. Collaborations between diagnostic companies, research institutes, and healthcare
- 5.1.4. Challenges
  - 5.1.4.1. Concerns pertinent to product failure and shortage of skilled professionals
5.2. Market Segmentation Analysis
- 5.2.1. Application: Increasing usage of immunohistochemistry in forensic science for the identification of tissue samples and body fluids at crime scenes
- 5.2.2. Product: Increasing demand for secondary antibodies for accurate and reliable results
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Immunohistochemistry Market, by Product

6.1. Introduction
6.2. Antibodies
- 6.2.1. Primary Antibodies
- 6.2.2. Secondary Antibodies
6.3. Equipment
- 6.3.1. Slide Scanners
- 6.3.2. Slide Staining Systems
- 6.3.3. Tissue Microarrays
- 6.3.4. Tissue Processing Systems
6.4. Kits
6.5. Reagents
- 6.5.1. Blocking Sera & Reagents
- 6.5.2. Chromogenic Substrates
- 6.5.3. Diluents
- 6.5.4. Fixation Reagents
- 6.5.5. Histological Stains
- 6.5.6. Organic Solvents
- 6.5.7. Proteolytic Enzymes
- 6.5.8. Stabilizers

7. Immunohistochemistry Market, by Disease Type

7.1. Introduction
7.2. Autoimmune Diseases
7.3. Cancer
7.4. Cardiovascular Diseases
7.5. Diabetes Mellitus
7.6. Infectious Diseases
7.7. Nephrological Diseases

8. Immunohistochemistry Market, by End-user

8.1. Introduction
8.2. Academic & Research Institutes
8.3. CROs
8.4. Forensic Labs
8.5. Hospitals & Diagnostic Laboratories
8.6. Pharma & Biopharma Companies

9. Immunohistochemistry Market, by Application

9.1. Introduction
9.2. Diagnostics
9.3. Drug Testing
9.4. Forensic

10. Americas Immunohistochemistry Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Immunohistochemistry Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Immunohistochemistry Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Tempus launches advanced HER2 and FOLR1 IHC tests to enhance precision medicine and targeted cancer therapies
- 13.3.2. Roche secures CE Mark for VENTANA HER2 (4B5) test, enhancing treatment options for HER2-low metastatic breast cancer with ENHERTU
- 13.3.3. Cell signaling technology introduces SignalStar Multiplex IHC technology
- 13.3.4. Danaher Corporation to acquire UK-based Abcam to enhance drug discovery and disease mapping capabilities
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Agilent Technologies Inc.
2. Becton, Dickinson & Company
3. Bio SB
4. Bio-Rad Laboratories Inc.
5. Bio-Techne Corporation
6. Biocare Medical LLC
7. Biogenex Laboratories
8. CANDOR Bioscience GmbH
9. Cell Signaling Technology, Inc.
10. Danaher Corporation
11. Diagnostic BioSystems Inc.
12. Eagle Biosciences, Inc.
13. Elabscience Biotechnology Inc.
14. F. Hoffman-La Roche AG
15. Genemed Biotechnologies, Inc. by Sakura Finetek Japan Co., Ltd
16. Histo-Line Laboratories
17. Lunaphore Technologies SA
18. Merck KGaA
19. Miltenyi Biotec B.V. & Co. KG
20. PerkinElmer Inc.
21. Rockland Immunochemicals, Inc.
22. Takara Bio, Inc
23. Thermofisher Scientific, Inc.